(Q38285510)

1 September 2017

1 reference

title

Role of phosphoproteomics in the development of personalized cancer therapies (English)

1 reference

1 September 2017

Pedro R Cutillas

1

1 reference

1 September 2017

publication date

27 February 2015

1 reference

Proteomics - Clinical Applications

1 September 2017

published in

1 reference

1 September 2017

volume

9

1 reference

1 September 2017

issue

3-4

1 reference

1 September 2017

page(s)

383-395

1 reference

The coming of age of phosphoproteomics--from large data sets to inference of protein functions

1 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

Phosphoproteomics-based network medicine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

Mapping in vivo signal transduction defects by phosphoproteomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

Biological signalling activity measurements using mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

Adaptive protein and phosphoprotein networks which promote therapeutic sensitivity or acquired resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

Approaches for measuring signalling plasticity in the context of resistance to targeted cancer therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

Shifting paradigms: the seeds of oncogene addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

The PIK3CA gene is mutated with high frequency in human breast cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

High frequency of mutations of the PIK3CA gene in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

Recurring mutations found by sequencing an acute myeloid leukemia genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

Accumulation of driver and passenger mutations during tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

Drugging the PI3 kinome: from chemical tools to drugs in the clinic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

Correlating phosphatidylinositol 3-kinase inhibitor efficacy with signaling pathway status: in silico and biological evaluations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

Phosphoproteomic analysis of leukemia cells under basal and drug-treated conditions identifies markers of kinase pathway activation and mechanisms of resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

Phosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

What a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

Personalized network-based treatments in oncology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

The Cancer Genome Atlas Pan-Cancer analysis project

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

Systematic identification of genomic markers of drug sensitivity in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

Can we deconstruct cancer, one patient at a time?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

A CXCL1 paracrine network links cancer chemoresistance and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

Cross-species proteomics reveals specific modulation of signaling in cancer and stromal cells by phosphoinositide 3-kinase (PI3K) inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

The pharmacological point of view of resistance to therapy in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

Feedbacks and adaptive capabilities of the PI3K/Akt/mTOR axis in acute myeloid leukemia revealed by pathway selective inhibition and phosphoproteome analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

Ultrasensitive and absolute quantification of the phosphoinositide 3-kinase/Akt signal transduction pathway by mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

Mass spectrometry for enzyme assays and inhibitor screening: an emerging application in pharmaceutical research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

Functional interrogation of the kinome using nucleotide acyl phosphates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

Adaptive reprogramming of the breast cancer kinome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

Mass spectrometry based method to increase throughput for kinome analyses using ATP probes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

Mass spectrometry-based proteomics and network biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

Modeling signaling networks using high-throughput phospho-proteomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

Is phosphoproteomics ready for clinical research?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

Towards defining biomarkers indicating resistances to targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

Analytical challenges translating mass spectrometry-based phosphoproteomics from discovery to clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

Single-step enrichment by Ti4+-IMAC and label-free quantitation enables in-depth monitoring of phosphorylation dynamics with high reproducibility and temporal resolution.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

Characterization of a TiO₂ enrichment method for label-free quantitative phosphoproteomics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

Evaluation of quantitative performance of sequential immobilized metal affinity chromatographic enrichment for phosphopeptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

Pathway-based biomarker search by high-throughput proteomics profiling of secretomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

Global phosphoproteomic profiling reveals distinct signatures in B-cell non-Hodgkin lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

Maximizing peptide identification events in proteomic workflows using data-dependent acquisition (DDA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

Quantitative profiling of proteins in complex mixtures using liquid chromatography and mass spectrometry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

Quantification of gel-separated proteins and their phosphorylation sites by LC-MS using unlabeled internal standards: analysis of phosphoprotein dynamics in a B cell lymphoma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

Advances in phosphopeptide enrichment techniques for phosphoproteomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

Effect of peptide-to-TiO2 beads ratio on phosphopeptide enrichment selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

Mass spectrometry in high-throughput proteomics: ready for the big time.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

Quantitative profile of five murine core proteomes using label-free functional proteomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

IDEAL-Q, an automated tool for label-free quantitation analysis using an efficient peptide alignment approach and spectral data validation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

LFQuant: a label-free fast quantitative analysis tool for high-resolution LC-MS/MS proteomics data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

A self-validating quantitative mass spectrometry method for assessing the accuracy of high-content phosphoproteomic experiments

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

Regulation of protein kinases; controlling activity through activation segment conformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

Weak functional constraints on phosphoproteomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

Discrete logic modelling as a means to link protein signalling networks with functional analysis of mammalian signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

Comparing signaling networks between normal and transformed hepatocytes using discrete logical models

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

Systematic Discovery of In Vivo Phosphorylation Networks

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

KinomeXplorer: an integrated platform for kinome biology studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

Kinase-substrate enrichment analysis provides insights into the heterogeneity of signaling pathway activation in leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

Profiles of Basal and stimulated receptor signaling networks predict drug response in breast cancer lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

Environmental stress affects the activity of metabolic and growth factor signaling networks and induces autophagy markers in MCF7 breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

Intratumor heterogeneity alters most effective drugs in designed combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

Dual blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

Selective Isolation at the Femtomole Level of Phosphopeptides from Proteolytic Digests Using 2D-NanoLC-ESI-MS/MS and Titanium Oxide Precolumns

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

Only a Subset of Met-Activated Pathways Are Required to Sustain Oncogene Addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

Utility of Accurate Mass Tags for Proteome-Wide Protein Identification

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201400104

21 January 2018

Identifiers

DOI

10.1002/PRCA.201400104

1 reference

release_6l55si6u7vesxjd2tzeq5qi6e4

1 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/6l55si6u7vesxjd2tzeq5qi6e4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference